The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
May 17th 2024
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Equivalent Safety, Efficacy Between Herceptin and Trastuzumab Biosimilar for Gastric Cancer
April 7th 2022A trastuzumab biosimilar was found to have similar safety and efficacy with the reference product (Herceptin) in patients with advanced gastric cancer, a population previously excluded from bioequivalence studies for trastuzumab biosimilars.
Read More
Dr Chelsee Jensen on the Solution to Stocking Multiple Biosimilars for the Same Reference Product
April 7th 2022Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, provides her take on why practices will have to continue to stock multiple biosimilars for the same reference product.
Watch
Infliximab Biosimilar Maintains Outcomes, Remission Status After Switch From Originator
March 24th 2022Patients switched from the originator product maintained their clinical outcomes and remissions status while biologic-naïve patients recorded positive responses and remission outcomes after initiating infliximab-dyyb.
Read More
Panel on Prior Authorization Reveals Role PBMs Play in Biosimilar Uptake in Oncology
March 22nd 2022During the recent Association of Community Cancer Centers’ 2022 Annual Meeting & Cancer Center Business Summit, panelists suggested that the laser focus on rebates by pharmacy benefit managers (PBMs) may be hindering uptake of biosimilars, thereby keeping some off of formulary lists.
Read More
Julie Reed Previews 2022: The Year of Expanded Access to Biosimilars
March 14th 2022As the United States awaits market introduction for adalimumab biosimilars in 2023, 2022 is going to be the year of expanding access to biosimilars, according to Julie M. Reed, the new executive director of the Biosimilars Forum.
Watch
The Biosimilars Forum's Julie Reed Predicts How Interchangeability Will Impact Biosimilar Uptake
February 25th 2022Julie M. Reed, the new executive director of the Biosimilars Forum, offers her opinion on how interchangeability will impact US biosimilar uptake now that the FDA has given the designation to 2 biosimilars.
Watch
CMS Official Cites OCM as Example of Biosimilar Success
February 21st 2022Purva Rawal, PhD, senior advisor and chief strategy officer, Center for Medicare and Medicaid Innovation, addressed attendees at the Association for Accessible Medicines' Access! annual meeting, held in Orlando, Florida, February 15-16.
Read More
VA Study: Patients Switching to Biosimilar Infliximab More Likely to Stop Treatment
February 11th 2022Physician and patient resistance to switching from an innovator or reference product to a biosimilar—or from one biosimilar to another—constitutes one of the major barriers to biosimilar adoption, despite the cost savings that can be achieved.
Read More
Real-world Usage of Bevacizumab-bvzr Biosimilar in US Oncology Practice
Real-world adoption of bevacizumab-bvzr biosimilar was retrospectively assessed, revealing switching between biosimilars and the reference product and utilization in extrapolated indications and combination regimens.
Read More
Payers, Value-based Care Policies Impact Biosimilar Adoption, Cardinal Health Report Finds
February 8th 2022Cardinal Health's report, “2022 Biosimilars Report: The U.S. Journey and Path Ahead,” outlines how biosimilars will move beyond their comfort zones in oncology and rheumatology and more boldly into therapeutic areas such as ophthalmology and diabetes care.
Read More
Panelists Explore What Exactly Is Holding Up US Adoption of Biosimilars
January 26th 2022Payer intervention, lack of patient savings, and confusion surrounding interchangeability are some of the many barriers standing in the way of US biosimilar uptake, with our group of panelists calling for big changes.
Read More
Patents Filed a Decade Post Originator Approval Account for Most Biosimilar Patent Lawsuits
January 21st 2022Researchers have found that most US patent infringement cases against biosimilar manufacturers cover patents filed over a decade after the originator product's FDA approval, leading to limits on competition among biologic drugs.
Read More
Ophthalmology Biobetters and Biosimilars May Be Just Around the Corner
January 12th 2022More biobetter drugs may be on the horizon, with an opportunity to snatch market share from reference products, and several biosimilars are under development for ophthalmic conditions, authors of a review concluded.
Read More